Medpace Valuation Multiples

Medpace Overview

About Medpace

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Founded

2014

HQ

Employees

6.2K

Website

medpace.com

Sectors

Contract Research & ManufacturingMedical DevicesBioTechHealthTech

Financials (LTM)

Revenue: $3B

EBITDA: $575M

EV

$14B

Valuation Multiples

Multiples.vc

Start free trial

Medpace Financials

Medpace reported last 12-month revenue of $3B and EBITDA of $575M.

In the same LTM period, Medpace generated $780M in gross profit, $575M in EBITDA, and $466M in net income.

Medpace P&L

In the most recent fiscal year, Medpace reported revenue of $3B and EBITDA of $563M.

Medpace expects next 12-month revenue of XXX and NTM EBITDA of XXX

Medpace Stock Performance

Medpace has current market cap of $15B, and enterprise value of $14B.

Medpace's stock price is $520.36.

Medpace Valuation Multiples

Medpace trades at 5.5x EV/Revenue multiple, and 25.2x EV/EBITDA.

Medpace Financial Valuation Multiples

As of April 18, 2026, Medpace has market cap of $15B and EV of $14B.

Equity research analysts estimate Medpace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medpace has a P/E ratio of 31.9x.

Medpace Margins & Growth Rates

Medpace's revenue in the last 12 month grew by 10%.

Medpace's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.0M for the same period.

Medpace's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medpace's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Medpace Public Comps

See public comps and valuation multiples for other Contract Research & Manufacturing and Medical Devices comps.

Medpace M&A Activity

Medpace acquired XXX companies to date.

Last acquisition by Medpace was on XXXXXXXX, XXXXX. Medpace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Medpace Investment Activity

Medpace invested in XXX companies to date.

Medpace made its latest investment on XXXXXXXX, XXXXX. Medpace invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).